13F-HR filed by TANG CAPITAL MANAGEMENT LLC
TANG CAPITAL MANAGEMENT LLC filed this 13F-HR for the quarter ended 2013-06-30, filed 2013-08-14, with 21 holding rows worth $253,799,000.
- Accession
- 0001214659-13-004661
- Filer
- CIK 1232621
- Filed
- 2013-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2013
A holdings report, 22 entries on the cover page, a total value of $253,799,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $253,799,000 with VALUE read as thousands by filing date, 13F file number 028-14822. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerTANG KEVIN C028-14818
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| PDL BIOPHARMA INC | 69329YAE4 | CNV | 30,974,000 | $43,580,000 | thousands by filing date | principal |
| MANNKIND CORP | 56400PAA0 | NOTE 3.750%12/1 | 34,144,000 | $33,632,000 | thousands by filing date | principal |
| OPKO HEALTH INC | 68375NAA1 | NOTE 3.0% 2/1/33 | 29,500,000 | $30,795,000 | thousands by filing date | principal |
| PACIRA PHARMACEUTICALS INC | 695127AA8 | NOTE 3.25% 2/1/19 | 18,500,000 | $25,756,000 | thousands by filing date | principal |
| SALIX PHARMACEUTICALS INC | 795435106 | COM | 300,000 | $19,845,000 | thousands by filing date | |
| DENDREON CORP | 24823QAC1 | CORPORATE OBLIG | 26,515,000 | $19,091,000 | thousands by filing date | principal |
| INTERMUNE INC | 45884XAE3 | NOTE 2.500% 9/1 | 17,000,000 | $14,068,000 | thousands by filing date | principal |
| NEKTAR THERAPEUTICS | 640268108 | COM | 911,053 | $10,523,000 | thousands by filing date | |
| DEPOMED INC | 249908104 | COM | 1,842,280 | $10,354,000 | thousands by filing date | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 182,300 | $10,161,000 | thousands by filing date | |
| ONCOGENEX PHARMACEUTICALS IN | 68230A106 | COM | 933,100 | $9,144,000 | thousands by filing date | |
| MANNKIND CORP | 56400P201 | COM | 1,184,784 | $7,707,000 | thousands by filing date | |
| ENDOCYTE INC | 29269A102 | COM | 465,763 | $6,115,000 | thousands by filing date | |
| SAVIENT PHARMACEUTICALS INC | 80517QAA8 | CNV | 30,476,000 | $4,571,000 | thousands by filing date | principal |
| CORSICANTO LTD SR CONV NT CONV DTD 7/15/2012 3.5% 1/15/2032 | 220480AC1 | CONVERTIBLE | 2,500,000 | $2,722,000 | thousands by filing date | principal |
| NAVIDEA BIOPHARMACEUTICALS I | 63937X103 | COM | 868,079 | $2,318,000 | thousands by filing date | |
| ROCKWELL MED INC | 774374102 | COM | 448,146 | $1,618,000 | thousands by filing date | |
| SUPERNUS PHARMACEUTICALS INC | 868459AA6 | NOTE 7.5% 5/1/19 | 10,000,000 | $1,253,000 | thousands by filing date | principal |
| DENDREON CORP | 24823Q107 | COM | 79,600 | $328,000 | thousands by filing date | |
| CYCLACEL PHARMACEUTICALS INC | 23254L306 | COM | 73,895 | $218,000 | thousands by filing date | |
| AMBIT BIOSCIENCES CORP | 02318X100 | COM | 46 | $0 | thousands by filing date | Value filed as zero, left out of ratios. |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001214659-13-004661 | this filing | 2013-08-14 | acceptance time not in the bulk data set |